ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,291.34
      0.45%
      US Tech 100
      18,238.80
      0.51%
      Dow Jones
      39,115.95
      0.13%
      Brent Oil
      81.755
      0.55%
      Bitcoin
      67,271.74
      -0.96%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Dr Reddys Laboratories Ltd (RDY)

      7. Dr Reddys Laboratories Ltd (RDY) News

      RDY

      Dr Reddys Laboratories (RDY)

      Dr Reddys Laboratories Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:RDY
      DateTimeSourceHeadlineSymbolCompany
      05/22/20241:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/21/202410:59AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/21/202410:49AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/21/202410:05AMBusiness WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNYSE:RDYDr Reddys Laboratories Ltd
      05/21/20248:00AMGlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNYSE:RDYDr Reddys Laboratories Ltd
      05/17/20249:21AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/15/20242:36PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/13/20243:07PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/13/20246:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/08/202412:23PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/08/20246:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/07/20242:37PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/07/202410:31AMBusiness WireDr. Reddy’s Q4 & Full Year FY24 Financial ResultsNYSE:RDYDr Reddys Laboratories Ltd
      05/07/20246:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      05/03/20248:00AMBusiness WireDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.NYSE:RDYDr Reddys Laboratories Ltd
      03/22/20247:00AMGlobeNewswire Inc.Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaNYSE:RDYDr Reddys Laboratories Ltd
      03/19/20247:00AMBusiness WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UKNYSE:RDYDr Reddys Laboratories Ltd
      03/04/20246:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      03/01/20246:22AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/29/20246:57AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/29/20246:22AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/26/20246:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/23/20246:22AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/21/20248:43AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/20/20246:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/15/20246:39AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/12/202412:16PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/05/202410:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      02/02/20246:07AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:RDYDr Reddys Laboratories Ltd
      01/31/20249:44AMBusiness WireDr. Reddy’s Q3 & 9M FY24 Financial ResultsNYSE:RDYDr Reddys Laboratories Ltd
       Showing the most relevant articles for your search:NYSE:RDY